Regeneron Pharmaceuticals, Inc. REGN reported third-quarter 2025 adjusted earnings per share (EPS) of $11.83, which comfortably beat the Zacks Consensus Estimate of $9.44. However, the bottom line was ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59. The company reported sales ...
Oct 28 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results